Walgreens Boots Alliance generates revenue through three principal operating segments, each with a distinct economic logic, customer base, and margin profile. Understanding the interplay between these segments is essential to grasping both the company's historical success and its current financial difficulties. The United States Segment — the Walgreens Drugstore Business The U.S. Segment, which operates under the Walgreens and Duane Reade brand names, is by far the largest contributor to consolidated revenues, accounting for roughly 80 percent of the total in fiscal year 2024. This segment generated approximately 116.8 billion dollars in revenue during the fiscal year ending August 31, 2024, driven by two distinct but interconnected revenue channels: pharmacy sales and front-of-store retail sales. Pharmacy sales constitute the dominant revenue driver within the U.S. Segment, representing approximately 76 to 78 percent of total U.S. Revenues in a typical fiscal year. Walgreens filled more than 800 million prescriptions in fiscal 2024 across its U.S. Locations — a staggering volume that places it among the highest-volume prescription dispensers in the country, trailing only CVS Pharmacy. The mechanics of pharmacy revenue generation are more complex than they appear at the retail level. When a customer fills a prescription at Walgreens, the company receives payment primarily from third-party payers — insurance companies, pharmacy benefit managers (PBMs), Medicare Part D plans, and Medicaid — rather than directly from the patient. The reimbursement rate the company receives from these payers for each prescription is determined through contractual negotiations and regulatory frameworks, and those rates have been under systematic downward pressure for more than a decade. Pharmacy benefit managers — entities such as Express Scripts (owned by Cigna), CVS Caremark, and OptumRx (owned by UnitedHealth Group) — act as the powerful intermediaries in this transaction. They negotiate formulary placements, set reimbursement rates for network pharmacies, and increasingly operate their own mail-order and specialty pharmacy services that compete directly with brick-and-mortar pharmacies like Walgreens. The PBM-driven reimbursement squeeze has been the single most destructive force affecting Walgreens' pharmacy economics over the past decade, compressing margins on individual prescription fills to the point where the profitability of the pharmacy business has become structurally challenged. Front-of-store retail — the consumables, over-the-counter medications, beauty products, snacks, beverages, and general merchandise sold outside the pharmacy counter — represents approximately 22 to 24 percent of U.S. Segment revenues. This business is far more straightforward in its economics, resembling a convenience retail operation with gross margins typically ranging from 25 to 30 percent on merchandise sales. However, front-of-store traffic has been in secular decline for years, pressured by Amazon's convenience, big-box retailers like Walmart and Target offering broader selection at competitive prices, and dollar stores capturing the value-seeking end of the convenience retail market. Walgreens has struggled to find a compelling reason for consumers to browse its front-of-store aisles when those same products are available online with next-day delivery or at lower prices elsewhere. The company also earns significant fee revenue from its loyalty program, myWalgreens, which had enrolled more than 100 million members as of recent reporting periods. Loyalty program data enables more targeted promotional marketing and creates a direct communication channel with customers that has modest but real monetization potential through partnerships and co-branded financial products, including the Walgreens Cash credit card issued in partnership with Synchrony Financial. The International Segment — Boots UK and European Operations The international segment is anchored by Boots, a beloved British pharmacy, health, and beauty retailer with a heritage dating to 1849. Boots operates approximately 2,200 stores across the United Kingdom, along with a significant e-commerce presence and a wholesale pharmaceutical distribution network in Europe. The segment generated approximately 6.2 billion dollars in fiscal 2024, representing about 4 percent of consolidated revenues. Boots occupies a unique and defensible position in the UK retail market. Unlike Walgreens in the United States, Boots has successfully cultivated a strong own-brand portfolio — the No7 skincare line being the most notable example — that commands premium pricing and fierce customer loyalty. No7 is among the best-selling skincare brands in the United Kingdom and has achieved meaningful distribution in the United States through Walgreens stores and online channels. The Boots Advantage Card loyalty program, with more than 17 million active members, is one of the most deeply embedded retail loyalty schemes in British consumer culture. The international segment has historically operated at better margin rates than the pressured U.S. Pharmacy business, and there have been periodic discussions about a potential IPO of Boots UK as a standalone entity that would unlock value for WBA shareholders. The U.S. Healthcare Segment — A Troubled Experiment Walgreens established a separate U.S. Healthcare segment in fiscal 2022 to house its investments in healthcare services companies, most prominently VillageMD (primary care clinics), Shields Health Solutions (specialty pharmacy services for health systems), and CareCentrix (home care services). The strategic vision was to transform Walgreens locations into integrated health hubs where patients could receive primary care, pick up specialty prescriptions, and access home health coordination services under one roof. The segment generated modest revenues — approximately 2.1 billion dollars in fiscal 2024 — but consumed enormous capital and generated substantial operating losses. VillageMD in particular burned cash at a rate that proved unsustainable. The company recognized billions in goodwill impairment charges related to VillageMD in fiscal 2023 and 2024, contributing directly to the company's reported net losses. By mid-2024, Walgreens had announced plans to close the majority of its VillageMD co-located clinics, writing off much of the capital invested in the strategy. Pharmaceutical Wholesale — Alliance Healthcare Through its 70 percent ownership stake in Alliance Healthcare (with the remaining 30 percent held by AmerisourceBergen/Cencora), WBA participates in pharmaceutical wholesale distribution across Europe. This business distributes medicines, health products, and related goods to pharmacies, hospitals, and health centers across more than a dozen European countries. The wholesale business is a high-volume, thin-margin operation — generating significant revenues but modest operating profit — that provides geographic diversification and supply chain integration benefits. Profit Generation and Margin Economics WBA's consolidated adjusted operating margin has hovered in the low single digits, reflecting the inherently low-margin nature of pharmacy distribution and retail. The company's ability to generate free cash flow has been severely constrained by capital expenditures related to the healthcare services buildout, debt service costs, and the restructuring charges associated with store closures and VillageMD wind-down activities. Management's current restructuring program targets annualized cost savings in excess of 1 billion dollars through store closures, workforce optimization, and supply chain efficiencies — savings that will be essential to restoring the company's cash generation capacity and reducing its debt burden.